Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents

Table 1

Randomized phase III clinical trials comparing platinum combinations to platinum monotherapy concurrently with external beam irradiation in patients with locally advanced cervical cancer.

Trial	Year	Experimental regimen	𝑁	FIGO stage	Primary outcome	Remarks
Morris et al. [12]	1999	Cisplatin; 5-FU	401	IB-IVA	5-year OS rate: 73%	Concurrent CRT decreased the rates for both local and distant recurrence
Rose et al. [11]	1999	Cisplatin; 5-FU; Hydroxyurea	526	IIB-IVA	5-year OS rate: 64%	Combination more toxic than cisplatin monotherapy
Whitney et al. [10]	1999	Cisplatin; 5-FU	388	IIB-IVA	5-year OS rate: 63%	Superior to hydroxyurea alone
Veerasarn et al. [26]	2007	Carboplatin; tegafur-uracil	469	IIB-IIIB	5-year PFS and OS were 76% and 93%, respectively	ORR, PFS, and OS not different to carboplatin alone
Kim et al. [28]	2008	Cisplatin; 5-FU	158	IIB-IVA	5-year OS rate: 70%	Cisplatin monotherapy equally efficient and less toxic
Lanciano et al. [13]	2005	Cisplatin; 5-FU (PVI)	NR	IIB-IVA	1-year PFS and OS were 76% and 93%, respectively	Prematurely terminated for futility compared to cisplatin
Dueñas-González et al. [33]	2011	Cisplatin; gemcitabine	515	IIB-IVA	3-year PFS rate: 74.4%	Significant OS benefit compared to cisplatin monotherapy; Combination group also received adjuvant chemotherapy

FIGO: International Federation of Gynecologic Oncology; CRT: chemoradiotherapy; OS: overall survival; PFS: progression-free survival; ORR: objective response rate; 5-FU: 5-fluorouracil; PVI: protracted venous infusion; 𝑁: number of patients.